Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Evonik is discontinuing keto acid manufacturing at its site in Hanau, Germany, by the end of 2025 and will lay off around 260 workers. The company is also looking at divestment and partnership options for its keto and pharma amino acid facilities in France and China, according to an Oct. 11 release.
Italian biopharma Chiesi is launching a new €400 million ($433 million) facility in Europe to make monoclonal antibodies, enzymes and other proteins, the company said Monday. The new site will employ 200 staffers by the end of 2025.
Indiana-headquartered SpectronRx is expanding to Europe with the radiopharma CDMO earmarking $50 million to build a radiolabeling facility for actinium-225 assets, the company told Endpoints Thursday. Construction in Mol, Belgium, is anticipated to be completed next month, with the site to be operational by the first quarter of 2025.
EuroAPI has appointed Olivier Falut as its new chief financial officer. He is replacing Evelyne Nguyen who will stay at the company until the end of October, according to a Wednesday release. The company is in its “year of transition” as it undergoes major restructuring.
Texas-based CDMO Matica Biotechnology has signed a new contract with biotech Mongoose Bio, the companies announced Wednesday. Matica Bio will manufacture lentiviruses for Mongoose Bio’s T cell receptor-engineered T cell therapy for cancer.
RadioPharma CDMO AtomVie has partnered with Radiopharm Ventures, the company said Tuesday. AtomVie will manufacture the clinical-stage 177 lutetium-conjugated B7-H3-targeting radio antibody, dubbed 177Lu-BetaBart.
Perspective Therapeutics’ manufacturing facility in Somerset, NJ, is now operational and has sent its first shipment, the company said Wednesday. The facility manufactures lead-203 and lead-212-labeled radiopharmaceuticals.
Cellular Origins and Fresenius Kabi have embarked on a new collaboration for cell therapy manufacturing, the companies announced Wednesday. Cellular Origins will integrate Fresenius Kabi’s cell therapy processing tech into its robotic manufacturing platform, with the aim to manufacture cell therapies on a larger scale.
CDMO Cambrex’s storage subsidiary Q1 Scientific has opened a new facility in Durham, NC, to expand storage capacity for pharmaceutical, medical device and life science customers in North America, Cambrex said Wednesday.